– USA, FL – Carevive Systems, the leading oncology-focused health technology company centered on understanding and improving the cancer patient experience, announced the appointment of Bruno Lempernesse as CEO.
Bruno Lempernesse, a veteran health technology executive at the forefront of real-world patient data, joins the co-founder, Madelyn Trupkin Herzfeld, in leading Carevive. Herzfeld will continue to serve as Director, and take on the role of Vice-Chairman, in which she will oversee oncology practice and health system network partnerships, and chair Carevive’s Strategic Advisory Board.
“Bruno is a seasoned, high-growth executive and is also an expert in generating and analyzing real-world data,” said Herzfeld, an oncology nurse with deep expertise in cancer care. “We have a meaningful vision to make cancer care better for patients and their families. Bruno’s experience in growing successful real-world evidence companies and my oncology expertise are the perfect complement to scale the company, and we have shared passion to ensure our vision becomes a reality. Despite the explosion in the new cancer treatments approved by regulators there is an unmet need for reporting of real-world patient experiences and outcomes with each of these treatments. As we look to the future, Carevive data will be key to providing those insights.”
The two will partner on corporate development relationships as well as the company’s overall growth strategy.
Under Lempernesse’s leadership, the company plans to accelerate its vision to collect and analyze real-world patient-reported outcomes and care pathways to continuously improve upon the cancer care experience across the United States. Lempernesse’s main focus will be scaling Carevive’s innovative cancer care digital platform, currently in use by dozens of health systems across the United States, to help cancer care teams monitor and manage their patients remotely between clinic visits. In addition to Carevive’s cancer care digital platform, he will focus on increasing Carevive’s remote patient management functionality, growing Carevive’s Oncology Pragmatic Trial Investigator Network, to conduct real-world studies evaluating patient experiences, and building stronger evidence for treatment and symptom pathways.
“Multiple stakeholders have an interest in connecting clinical data and patient-reported outcomes data, including life science companies, clinicians, and payers, to improve patient care,” said Bruno Lempernesse. “With a committed team, board and co-founder, Carevive will reshape the way cancer care is delivered, and make treatments and therapies more personalized. I’m pinching myself knowing that I found a company with not only massive growth potential but with the patient at the center – the possibilities are endless.”
About Bruno Lempernesse
Formerly SVP and General Manager at SHYFT Analytics, Bruno Lempernesse joins Carevive from Acorn AI, a Medidata company, having led their commercial data solutions division. His 25-year experience at the intersection of real-world patient data analytics and corporate leadership leaves him perfectly positioned to bring Carevive’s technologies to the entire cancer care ecosystem. His other experiences in advancing healthcare data analytics include serving as CEO at Inflexxion and multiple executive global roles at Cegedim.
About Carevive Systems
Carevive Systems, founded in 2013, is an oncology-focused health technology company focused on understanding and improving the cancer patient experience. Our platform enables providers to monitor and manage their patients remotely, which improves survival outcomes and patient quality of life. The use of Carevive in the clinic unlocks critical data on the real-world cancer patient experience to continuously improve patient care today and advance cancer drug development.
For more information: https://www.carevive.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
